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Abstract
Colorectal cancer is one of the most frequent neoplasms and an important cause of mortality in the developed world.
Mendelian syndromes account for about 5% of the total burden of CRC, being Lynch syndrome and familial adenomatous
polyposis the most common forms. Lynch syndrome tumors develop mainly as a consequence of defective DNA mismatch
repair associated with germline mutations in MLH1, MSH2, MSH6 and PMS2. A significant proportion of variants identified by
screening these genes correspond to missense or noncoding changes without a clear pathogenic consequence, and they
are designated as ‘‘variants of uncertain significance’’, being the c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene a
clear example. The implication of this variant as a low-penetrance risk variant for CRC was assessed in the present study by
performing a case-control study within a large cohort from the COGENT consortium-COST Action BM1206 including 18,723
individuals (8,055 colorectal cancer cases and 10,668 controls) and a case-only genotype-phenotype correlation with several
clinical and pathological characteristics restricted to the Epicolon cohort. Our results showed no involvement of this variant
as a low-penetrance variant for colorectal cancer genetic susceptibility and no association with any clinical and pathological
characteristics including family history for this neoplasm or Lynch syndrome.
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Colorectal cancer (CRC) is one of the most frequent neoplasms
and an important cause of mortality in the developed world. This
cancer is caused by both genetic and environmental factors
although 35% of the variation in CRC susceptibility involves
inherited genetic differences. Mendelian syndromes account for
about 5% of the total burden of CRC, being Lynch syndrome and
familial adenomatous polyposis the most common forms. Lynch
syndrome tumors develop mainly as a consequence of defective
DNA mismatch repair (MMR) associated with germline mutations
in the MLH1, MSH2, MSH6 and PMS2 genes [1]. Once clinical
criteria for this syndrome are complied, genetic screening of these
genes is performed when a MMR defect is detected in the patient’s
tumor. When a pathogenic variant is detected, management of this
disease can be significantly improved by identifying carriers that
will benefit from specific screening, preventive, and therapeutic
measures. Also, identifying non-carriers in additional family
members permit to release these individuals from intensive
surveillance. Noteworthy, a significant proportion of variants
identified in the MMR genetic screening correspond to missense
or noncoding changes without a clear pathogenic consequence,
and they are designated as ‘‘variants of uncertain significance’’
(VUS). Therefore, differentiating pathogenic and neutral genetic
variants is still a major challenge in clinical genetics [2].
The c.1852_1853delinsGC (p.K618A) variant in the MLH1
gene corresponds to a clear example of VUS in Lynch syndrome.
When consulting the Leiden Open Variation Database (LOVD
v.2.0), there are 120 entries for this variant [3]. Available past
studies reached contradictory conclusions about its pathogenicity
reporting harmful in silico predictions [4], absence of splicing or
mRNA alteration [5], presence in patients with a defective MMR
tumor [6], co-occurrence with clearly pathogenic MMR mutations
[7], apparent segregation with disease [8], and a majority of non-
altered in vitro functional studies [9,10]. All previous data permitted
to categorize it in LOVD as a class 1 variant (non-pathogenic/low
clinical significance) [11]. Therefore, it should be considered as a
neutral variant in terms of its implication with Lynch syndrome.
Recently, genome-wide association studies (GWAS) successfully
identified so far 30 common, low-penetrance susceptibility variants
in 25 risk loci for CRC [12–19]. Some genetic variants in
hereditary CRC genes labeled as VUS could constitute low-
penetrance risk alleles for CRC. Indeed, this hypothesis has been
previously tested for some variants in those genes [20]. In
agreement with this rationale, the main aim of the present study
was to assess the implication of the c.1852_1853delinsGC
(p.K618A) variant in the MLH1 gene as a low-penetrance risk
variant for CRC by performing a case-control study within a large
cohort from the COGENT consortium-COST Action BM1206,
an international effort to facilitate the study of inherited genetic
predisposition to CRC [21,22].
Materials and Methods
Study population
The current genetic association study totalized 8,055 CRC cases
and 10,668 controls from 7 different cohorts (Edinburgh,
Epicolon, Groningen, Kiel, Leiden, Milano, Stockholm) and
recruitment details are summarized below. The study was
approved by the institutional ethical committee of each partici-
pating hospital and written informed consent was obtained from
all patients.
Edinburgh cohort (1,553 CRC cases and 932 controls). A
population-based series of patients from throughout Scotland, who
were diagnosed with colorectal cancer when they were less than 55
years of age, were recruited to the study between February 1999
and June 2004. During the same period, unaffected controls were
ascertained from a population-based register (community health
index) and were invited to participate.
Epicolon (2,001 CRC cases and 1,647 controls). Cases
and controls were recruited through the EPICOLON Consortium
that is based on a prospective, multicenter and population-based
epidemiology survey of the incidence and features of CRC in the
Spanish population [23]. Briefly, cases were selected as patients
with de novo histologically confirmed diagnosis of colorectal
adenocarcinoma. Exclusion criteria were hereditary CRC forms,
such as Lynch syndrome and familial adenomatous polyposis
(FAP) and a personal history of inflammatory bowel disease.
Controls were from the Spanish National DNA bank and were
confirmed not to have cancer or history of neoplasm and no family
history of CRC. All cases and controls were of Caucasian
ethnicity.
Groningen (559 CRC cases and 501 controls). Unselected
CRC cases and hospital patient controls from the Netherlands
included in the SCOPE project.
Kiel (1,768 CRC cases and 2.030 controls). Cases and
controls from population-based biobank projects including POP-
GEN (Population Genetic Cohort) from Schleswig-Holstein, north
Germany, and SHIP (Survey of Health in Pommerania) from east
and north-east Germany.
Leiden (505 CRC cases and 836 controls). Cases and
controls were recruited as previously described [24]. Briefly, most
of the cases were recruited through the clinical genetics
department. All cases were diagnosed with CRC and had early
onset and/or positive family history for CRC. Known dominant
polyposis syndromes, HNPCC/Lynch syndrome or bi-allelic
MutYH mutation carriers were excluded. A single proband from
each family was included in this study. Controls were healthy
blood donors from the southwest region of the Netherlands. All
cases and controls were of Caucasian ethnicity.
Milano (619 CRC cases and 2,526 controls). Briefly, the
cases were consecutive individuals affected with CRC who
underwent surgery at the Fondazione IRCCS Istituto Nazionale
Tumori in Milan (INT). The controls were blood donors recruited
through the Immunohematology and Transfusion Medicine
Service of INT the Associazione Volontari Italiani Sangue
Comunale in Milan. All cases and controls were of Caucasian
ethnicity.
Stockholm (1,729 CRC cases and 1,487
controls). Unselected cases ascertained through 12 hospitals
serving the Stockholm-Gotland and Uppsala-O¨rebro health-care
regions in Sweden and blood donor controls.
Genotyping
DNA was obtained from peripheral blood by standard
extraction procedures. Allelic discrimination to genotype the
c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene was
performed by using a custom assay with the TaqMan allelic
discrimination system (Life Technologies, Foster City, USA). As
quality control, DNA from a known carrier of this variant was
used as positive control, as well as duplicates and negative controls
for amplification. Data could be available upon request. An
example of allelic discrimination for this variant is shown in
Figure 1.
Statistical analysis
To test the association between the c.1852_1853delinsGC
(p.K618A) variant in the MLH1 gene and CRC risk, odds ratios
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(OR) and 95%CI were calculated for each genotype by using
PLINK v1.07 [25], separately in each cohort and globally. No
deviation of the genotype frequency in controls from those
expected under Hardy-Weinberg equilibrium (HWE) was detected
by x2 test (1 df) (P-value = 0.6294) [26].
In order to explore if personal and/or familial characteristics
were associated with the presence of the c.1852_1853delinsGC
(p.K618A) variant in the MLH1 gene, univariate analysis was
performed restricted to the CRC cases from the Epicolon cohort
due to data availability in this cohort. The selected clinical
variables to be evaluated were gender, age (dichotomized by 50
y.o.), location of CRC, previous neoplasm, previous/synchronous
adenoma, CRC familiy history (any relative with CRC), Lynch
syndrome family history (any relative affected), microsatellite
instability (MSI) and TNM tumor stage. Categorical variables
were compared by the x2 test (1 df), applying the Yates’ correction
when needed. All P-values were two-sided, and a value less than
0.05 was considered statistically significant. Calculations were
performed using the SPSS software version 18.0 (SPSS Inc,
Chicago, Ill).
Results and Discussion
Genotyping for the c.1852_1853delinsGC (p.K618A) variant in
the MLH1 gene was successful in 8,055 CRC cases and 10,668
controls from 7 independent cohorts. Percentage of carriers varied
between 0.4–2.6% in CRC cases and 0.5–3.1% for controls in the
different cohorts, being 1.4% and 1.5% in the entire cohort for
CRC cases and controls, respectively. Genotypic association
results are shown in Table 1 for each cohort and globally. No
association of this variant with CRC risk was detected neither in a
specific cohort nor globally.
In order to further explore the putative implication of this
MLH1 variant with CRC risk, we performed a case-only genotype-
phenotype correlation restricted to the Epicolon cohort (2,001
CRC cases) with several clinical and pathological characteristics.
Results are shown in Table 2. Again, none of the analyzed
variables showed a distinct association with the presence of the
c.1852_1853delinsGC (p.K618A) variant. Results for CRC family
history and Lynch syndrome family history were statistically
significant but the presence of any of these variables was linked
Figure 1. Allelic discrimination for c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene by using the TaqMan system. Red dots
correspond to non-carriers (AA/AA genotype) and green dots to heterozygous carriers (AA/GC).
doi:10.1371/journal.pone.0095022.g001
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with the wild-type genotype (AA/AA). The rest of variables
showed a similar distribution between carriers and non-carriers.
Obviously, genetic variants causing a missense mutation have a
less clear pathogenic interpretation than those causing a prema-
ture termination of the protein. The c.1852_1853delinsGC
(p.K618A) variant in the MLH1 gene is a prominent example of
a VUS that has been controversial for many years in the context of
Lynch syndrome genetic diagnosis. However, recent functional
studies have permitted to characterize more thoroughly its real
effect of the MLH1 protein and it can be concluded that its effect
is neutral or with very subtle effect [5,8–11].
Regarding its putative implication in CRC risk as a rare low-
penetrance variant, previous studies were sparse and included a
small number of CRC cases and controls [27,28]. Consequently, it
was justified to perform a case-control association study in a large
cohort in order to reach more solid conclusions. Our results
showed no involvement of this variant in CRC risk as a low-
penetrance variant in the MLH1 gene.
Regarding its putative implication in familial CRC, this variant
was also seen to be over-represented in families with suspected
Lynch syndrome in a previous study [29]. Our results will be not
in agreement with this previous observation since the K618A
variant was not linked in the Epicolon cohort to the presence of
CRC family history and Lynch syndrome family history.
Therefore, our study is adding to the existing literature by
showing that this variant is not linked to familial CRC.
Finally, we can conclude from our results and previous evidence
that the c.1852_1853delinsGC (p.K618A) variant in the MLH1
gene should be regarded from now on as a polymorphism without
functional effect on the MLH1 protein, no role in genetic
predisposition to Lynch syndrome, as well as no apparent effect
as a low-penetrance variant for CRC genetic susceptibility.
Table 1. Genotypic association results for the MLH1 c.1852_1853delinsGC (p.K618A) variant in 18,723 individuals from 7 cohorts.
Cohort Controls % Cases % OR lower upper P-value
Edinburgh
AA/AA 1,539 99.1 916 98.3 1.000 0.087
AA/GC 14 0.9 16 1.7 1.904 0.934 3.884
Total 1,553 932
Epicolon
AA/AA 1,596 96.9 1,949 97.4 1.000 0.368
AA/GC 51 3.1 52 2.6 0.839 0.574 1.228
Total 1,647 2,001
Groningen
AA/AA 555 99.3 497 99.2 1.000 1.000
AA/GC 4 0.7 4 0.8 1.116 0.281 4.438
Total 559 501
Kiel
AA/AA 2,003 98.7 1,752 99.1 1.000 0.282
AA/GC 27 1.3 16 0.9 0.680 0.368 1.259
Total 2,030 1,768
Leiden
AA/AA 832 99.5 503 99.6 1.000 1.000
AA/GC 4 0.5 2 0.4 0.828 0.152 4.503
Total 836 505
Milano
AA/AA 2,526 98.8 614 99.2 1.000 0.525
AA/GC 30 1.2 5 0.8 0.688 0.268 1.767
Total 2,556 619
Stockholm
AA/AA 1,466 98.6 1,700 98.3 1.000 0.571
AA/GC 21 1.4 29 1.7 1.188 0.680 2.074
Total 1,487 1,729
GLOBAL
AA/AA 10,517 98.6 7,931 98.5 1.000 0.501
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Table 2. Genotype-phenotype correlation of the MLH1 c.1852_1853delinsGC (p.K618A) variant with clinical and pathological
characteristics in colorectal cancer cases from the Epicolon cohort.
CRC#50 % CRC.50 % OR lower upper P-value
Age
AA/AA 97 5 1,841 95 1.000 1.000
AA/GC 2 3.8 50 96.2 1.317 0.316 5.493
Total 99 1,891
Female % Male % OR lower upper P-value
Gender
AA/AA 766 39.5 1,172 60.5 1.000 0.388
AA/GC 17 32.7 35 67.3 1.346 0.749 2.419
Total 783 1,207
Colon % Rectum % OR lower upper P-value
CRC location
AA/AA 1,267 65.9 656 34.1 1.000 0.882
AA/GC 33 64.7 18 35.3 1.053 0.589 1.885
Total 1,300 674
No % Yes % OR lower upper P-value
Previous neoplasm
AA/AA 1,290 73.8 458 26.2 1.000 0.624
AA/GC 39 78 11 22 0.794 0.403 1.564
Total 1,329 469
No % Yes % OR lower upper P-value
Prev/sync adenoma
AA/AA 1,268 71.2 513 28.8 1.000 0.112
AA/GC 41 82 9 18 0.543 0.262 1.124
Total 1,309 522
No % Yes % OR lower upper P-value
CRC FH
AA/AA 1,652 85.2 286 14.8 1.000 0.026
AA/GC 50 96.2 2 3.8 0.231 0.056 0.955
Total 1,702 288
No % Yes % OR lower upper P-value
Lynch FH
AA/AA 1,401 81.5 317 18.5 1.000 0.048
AA/GC 42 93.3 3 6.7 0.316 0.097 1.025
Total 1,443 320
No % Yes % OR lower upper P-value
MSI
AA/AA 1,308 94 84 6 1.000 0.731
AA/GC 37 92.5 3 7.5 1.263 0.381 4.180
Total 1,345 87
I–II % III–IV % OR lower upper P-value
TNM
AA/AA 909 53.7 783 46.3 1.000 1.000
AA/GC 26 53.1 23 46.9 1.027 0.581 1.814
Total 935 806
CRC, colorectal cancer; OR, odds ratio; Prev/Sync, Previous/Synchronous; FH, family history; MSI, microsatellite instability; TNM, tumor-node-metastasis.
doi:10.1371/journal.pone.0095022.t002
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